Molecular and neuroendocrine mechanisms of cancer cachexia

Journal of Endocrinology

Volumn 226, Issue 3, 2015, Pages R29-R43

  Mendes, Maria Carolina S ^a   Pimentel, Gustavo D ^a   Costa, Felipe O ^a   Carvalheira, José B C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMORELIN; DEXAMETHASONE; GHRELIN; HUMORAL ANTIBODY; METFORMIN; PARATHYROID HORMONE RELATED PROTEIN; ROSIGLITAZONE;

ADIPOSE TISSUE; ANOREXIA; CACHEXIA; CANCER THERAPY; CLINICAL TRIAL (TOPIC); FOOD INTAKE; HUMAN; HYPOTHALAMUS; METABOLISM; MUSCLE; MUSCLE ATROPHY; NEUROENDOCRINE SYSTEM; NONHUMAN; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SARCOPENIA; SKELETAL MUSCLE; THERMOGENESIS; WHITE ADIPOSE TISSUE; COMPLICATION; ENERGY METABOLISM; NEOPLASM; PHYSIOLOGY;

ADIPOSE TISSUE; CACHEXIA; ENERGY METABOLISM; HUMANS; MUSCLE, SKELETAL; NEOPLASMS;

EID: 84944550079     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-15-0170     Document Type: Review

References (197)

1. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S & Guttridge DC 2004 Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. Journal of Clinical Investigation 114 370-378. doi:10.1172/JCI200420174
2. Agustsson T, Rydén M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, Isaksson B, Permert J & Arner P 2007 Mechanism of increased lipolysis in cancer cachexia. Cancer Research 67 5531-5537. doi:10.1158/0008-5472.CAN-06-4585
3. Anand BK & Brobeck JR 1951 Hypothalamic control of food intake in rats and cats. Yale Journal of Biology and Medicine 24 123-140.
4. Andreyev HJ, Norman AR, Oates J & Cunningham D 1998 Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? European Journal of Cancer 34 503-509. doi:10.1016/S0959-80499710090-9
5. Argilés JM, Busquets S, Stemmler B & López-Soriano FJ 2014 Cancer cachexia: understanding the molecular basis. Nature Reviews. Cancer 14 754-762. doi:10.1038/nrc3829
6. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G, Serna-Thomé MG, Flores-Estrada D, Diaz-Romero C, Rodríguez CM,Martínez L & Sánchez- Lara K 2010 Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10 50. doi:10.1186/1471-2407-10-50
7. Arruda AP, Milanski M, Coope A, Torsoni AS, Ropelle E, Carvalho DP, Carvalheira JB & Velloso LA 2011 Low-grade hypothalamic inflammation leads to defective thermogenesis, insulin resistance, and impaired insulin secretion. Endocrinology 152 1314-1326. doi:10.1210/ en.2010-0659
8. Asakawa A, Fujimiya M, Niijima A, Fujino K, Kodama N, Sato Y, Kato I, Nanba H, Laviano A, Meguid MM et al. 2010 Parathyroid hormonerelated protein has an anorexigenic activity via activation of hypothalamic urocortins 2 and 3. Psychoneuroendocrinology 35 1178-1186. doi:10.1016/j.psyneuen.2010.02.003
9. Asp ML, Tian M, Wendel AA & Belury MA 2010 Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. International Journal of Cancer 126 756-763. doi:10.1002/ijc.24784
10. Baboota RK, Murtaza N, Jagtap S, Singh DP, Karmase A, Kaur J, Bhutani KK, Boparai RK, Premkumar LS, Kondepudi KK et al. 2014 Capsaicininduced transcriptional changes in hypothalamus and alterations in gut microbial count in high fat diet fed mice. Journal of Nutritional Biochemistry 25 893-902. doi:10.1016/j.jnutbio.2014.04.004
11. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H & Martignoni ME 2008 Cachexia worsens prognosis in patients with resectable pancreatic cancer. Journal of Gastrointestinal Surgery 12 1193-1201. doi:10.1007/s11605-008-0505-z
12. Balthasar N, Dalgaard LT, Lee CE, Yu J, Funahashi H,Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD et al. 2005 Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123 493-505. doi:10.1016/j.cell.2005.08.035
13. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M & Trayhurn P 2005 Zinc-a2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human SGBS adipocytes. FEBS Letters 579 41-47. doi:10.1016/j.febslet.2004.11.042
14. Barber MD, Ross JA, Voss AC, Tisdale MJ & Fearon KC 1999 The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. British Journal of Cancer 81 80-86. doi:10.1038/sj.bjc.6690654
15. Bayliss TJ, Smith JT, SchusterM, Dragnev KH & Rigas JR 2011 A humanized anti-IL-6 antibody ALD518 in non-small cell lung cancer. Expert Opinion on Biological Therapy 11 1663-1668. doi:10.1517/14712598. 2011.627850
16. Beck SA, Smith KL & Tisdale MJ 1991 Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Research 51 6089-6093.
17. BeiroaD, Imbernon M,Gallego R, Senra A,HerranzD,Villarroya F, Serrano M, Fernø J, Salvador J, Escalada J et al. 2014 GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 63 3346-3358. doi:10.2337/db14-0302
18. Bianchi A, Bruce J, Cooper AL, Childs C, KohliM,Morris ID, Morris-Jones P & Rothwell NJ 1989 Increased brown adipose tissue activity in children with malignant disease. Hormone and Metabolic Research 21 640-641. doi:10.1055/s-2007-1009308
19. Bing C, Russell ST, Beckett EE, Collins P, Taylor S, Barraclough R, TisdaleMJ & Williams G 2002 Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. British Journal of Cancer 86 612-618. doi:10.1038/sj. bjc.6600101
20. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ & Trayhurn P 2004 Zinc-a2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. PNAS 101 2500-2505. doi:10.1073/pnas. 0308647100
21. Bing C, Mracek T, Gao D & Trayhurn P 2010 Zinc-a2-glycoprotein: an adipokine modulator of body fat mass? International Journal of Obesity 34 1559-1565. doi:10.1038/ijo.2010.105
22. Blanco Martínez de Morentin P, González CR, Saha AK, Martins L, Diéguez C, Vidal-Puig A, Tena-Sempere M & López M 2011 Hypothalamic AMP-activated protein kinase as a mediator of whole body energy balance. Reviews in Endocrine & Metabolic Disorders 12 127-140. doi:10.1007/s11154-011-9165-5
23. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K et al. 2001 Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 1704-1708. doi:10.1126/science.1065874
24. Booth K, Maguire PM, Butterworth T & Hillier VF 1996 Perceived professional support and the use of blocking behaviours by hospice nurses. Journal of Advanced Nursing 24 522-527. doi:10.1046/j.1365- 2648.1996.22012.x
25. Braun TP, Zhu X, Szumowski M, Scott GD, Grossberg AJ, Levasseur PR, Graham K, Khan S, Damaraju S, Colmers WF et al. 2011 Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. Journal of Experimental Medicine 208 2449-2463. doi:10.1084/jem.20111020
26. Brooks SL, Neville AM, Rothwell NJ, Stock MJ&Wilson S 1981 Sympathetic activation of brown-adipose-tissue thermogenesis in cachexia. Bioscience Reports 1 509-517. doi:10.1007/BF01121584
27. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ et al. 2004 IKKb/NF-kB activation causes severe muscle wasting in mice. Cell 119 285-298. doi:10.1016/j.cell. 2004.09.027
28. Cao L, Choi EY, Liu X, Martin A, Wang C, Xu X & DuringMJ 2011 White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte axis. Cell Metabolism 14 324-338. doi:10.1016/j.cmet.2011.06.020
29. Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ & Tisdale MJ 1997 Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. British Journal of Cancer 76 606-613. doi:10.1038/bjc.1997.433
30. Carlson CJ, Booth FW & Gordon SE 1999 Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. American Journal of Physiology 277 R601-R606.
31. Chamberlain K 2004 Food and health: expanding the agenda for health psychology. Journal of Health Psychology 9 467-481. doi:10.1177/ 1359105304044030
32. Chen JL, Walton KL, Winbanks CE, Murphy KT, Thomson RE, Makanji Y, Qian H, Lynch GS, Harrison CA & Gregorevic P 2014 Elevated expression of activins promotes muscle wasting and cachexia. FASEB Journal 28 1711-1723. doi:10.1096/fj.13-245894
33. Cheung WW, Kuo HJ, Markison S, Chen C, Foster AC, Marks DL & Mak RH 2007 Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. Journal of the American Society of Nephrology 18 2517-2524. doi:10.1681/ ASN.2006091024
34. Cheung WW, Rosengren S, Boyle DL & Mak RH 2008 Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney International 74 180-186. doi:10.1038/ki.2008.150
35. Churm D, Andrew IM, Holden K, Hildreth AJ & Hawkins C 2009 A questionnaire study of the approach to the anorexia-cachexia syndrome in patients with cancer by staff in a district general hospital. Supportive Care in Cancer 17 503-507. doi:10.1007/s00520-008-0486-1
36. Cone RD 2005 Anatomy and regulation of the central melanocortin system. Nature Neuroscience 8 571-578. doi:10.1038/nn1455
37. Costa G & Donaldson SS 1979 Current concepts in cancer: effects of cancer and cancer treatment on the nutrition of the host. New England Journal of Medicine 300 1471-1474. doi:10.1056/ NEJM197906283002606
38. Costa G & Holland JF 1962 Effects of Krebs-2 carcinoma on the lipide metabolism of male Swiss mice. Cancer Research 22 1081-1083.
39. Davis M, Lasheen W, Walsh D, Mahmoud F, Bicanovsky L & Lagman R 2012 A phase II dose titration study of thalidomide for cancerassociated anorexia. Journal of Pain and Symptom Management 43 78-86. doi:10.1016/j.jpainsymman.2011.03.007
40. DeBoer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui A, Taylor JE, Halem HA, Dong JZ, Datta R et al. 2007 Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148 3004-3012. doi:10.1210/ en.2007-0016
41. DeBoer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G,Mitch WE, Taylor JE, Halem HA, Dong JZ et al. 2008 Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149 827-835. doi:10.1210/en.2007-1046
42. DeBoer MD, Scarlett JM, Levasseur PR, Grant WF & Marks DL 2009 Administration of IL-1b to the 4th ventricle causes anorexia that is blocked by agouti-related peptide and that coincides with activation of tyrosine-hydroxylase neurons in the nucleus of the solitary tract. Peptides 30 210-218. doi:10.1016/j.peptides.2008.10.019
43. Dechaphunkul T, Martin L, Alberda C, Olson K, Baracos V & Gramlich L 2013 Malnutrition assessment in patients with cancers of the head and neck: a call to action and consensus. Critical Reviews in Oncology/Hematology 88 459-476. doi:10.1016/j.critrevonc.2013.06.003
44. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ et al. 1980 Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. American Journal of Medicine 69 491-497. doi:10.1016/S0149-29180580001-3
45. Dodd GT, Decherf S, Loh K, Simonds SE, Wiede F, Balland E, Merry TL, Münzberg H, Zhang ZY, Kahn BB et al. 2015 Leptin and insulin act on POMC neurons to promote the browning of white fat. Cell 160 88-104. doi:10.1016/j.cell.2014.12.022
46. Doehner W & Anker SD 2002 Cardiac cachexia in early literature: a review of research prior to Medline. International Journal of Cardiology 85 7-14. doi:10.1016/S0167-52730200230-9
47. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE & Kumar A 2007 TNF-related weak inducer of apoptosis TWEAK is a potent skeletal muscle-wasting cytokine. FASEB Journal 21 1857-1869. doi:10.1096/fj. 06-7537com
48. Eley HL & Tisdale MJ 2007 Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. Journal of Biological Chemistry 282 7087-7097. doi:10.1074/jbc.M610378200
49. Eley HL, Russell ST & TisdaleMJ 2007 Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochemical Journal 407 113-120. doi:10.1042/BJ20070651
50. Eley HL, Russell ST & Tisdale MJ 2010 Mechanism of activation of dsRNAdependent protein kinase PKR in muscle atrophy. Cellular Signalling 22 783-790. doi:10.1016/j.cellsig.2010.01.002
51. Elmquist JK, Scammell TE & Saper CB 1997 Mechanisms of CNS response to systemic immune challenge: the febrile response. Trends in Neurosciences 20 565-570. doi:10.1016/S0166-22369701138-7
52. Enomoto A, Rho MC, Fukami A, Hiraku O, Komiyama K & Hayashi M2004 Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3- acetate-a novel nonpeptide IL-6 receptor antagonist. Biochemical and Biophysical Research Communications 323 1096-1102. doi:10.1016/ j.bbrc.2004.08.196
53. Fan XT, Huang XP, Da Silva C & Castagna M 1990 Arachidonic acid and related methyl ester mediate protein kinase C activation in intact platelets through the arachidonate metabolism pathways. Biochemical and Biophysical Research Communications 169 933-940. doi:10.1016/ 0006-291X9091983-Y
54. Fearon KC 2011 Cancer cachexia and fat-muscle physiology. New England Journal of Medicine 365 565-567. doi:10.1056/NEJMcibr1106880
55. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G et al. 2011 Definition and classification of cancer cachexia: an international consensus. Lancet. Oncology 12 489-495. doi:10.1016/S1470-20451070218-7
56. Fearon K, Arends J & Baracos V 2013 Understanding the mechanisms and treatment options in cancer cachexia. Nature Reviews. Clinical Oncology 10 90-99. doi:10.1038/nrclinonc.2012.209
57. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K & Dannenberg AJ 2001 Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clinical Cancer Research 7 3349-3355.
58. Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A, Yada T, Maejima Y, Sedbazar U, Sakai T et al. 2011 Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Translational Psychiatry 1 e23. doi:10.1038/tp.2011.25
59. Gallot YS, Durieux AC, Castells J, Desgeorges MM, Vernus B, Plantureux L, Rémond D, Jahnke VE, Lefai E, Dardevet D et al. 2014 Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Research 74 7344-7356. doi:10.1158/0008-5472.CAN-14-0057
60. Garcia JM, Garcia-TouzaM, Hijazi RA, Taffet G, Epner D,Mann D, Smith RG, Cunningham GR & Marcelli M 2005 Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. Journal of Clinical Endocrinology and Metabolism 90 2920-2926. doi:10.1210/jc.2004-1788
61. Garcia JM, Friend J & Allen S 2013 Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Supportive Care in Cancer 21 129-137. doi:10.1007/s00520-012-1500-1
62. Hale LP 2002 Zinc a-2-glycoprotein regulates melanin production by normal and malignant melanocytes. Journal of Investigative Dermatology 119 464-470. doi:10.1046/j.1523-1747.2002.01813.x
63. Hardie DG 2015 AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. Current Opinion in Cell Biology 33 1-7. doi:10.1016/j.ceb.2014.09.004
64. Hart BL 1988 Biological basis of the behavior of sick animals. Neuroscience and Biobehavioral Reviews 12 123-137. doi:10.1016/S0149- 76348880004-6
65. Hauner H, Petruschke T, Russ M, Röhrig K & Eckel J 1995 Effects of tumour necrosis factor alpha TNFa on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 38 764-771. doi:10.1007/s001250050350
66. Hervey GR 1959 The effects of lesions in the hypothalamus in parabiotic rats. Journal of Physiology 145 336-352. doi:10.1113/jphysiol.1959. sp006145
67. Hirai K, Hussey HJ, Barber MD, Price SA & Tisdale MJ 1998 Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Research 58 2359-2365.
68. Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Fujiwara Y, Mori M et al. 2012 Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 118 4785-4794. doi:10.1002/cncr.27430
69. Hopkinson JB,Wright DN, McDonald JW & Corner JL 2006 The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. Journal of Pain and Symptom Management 32 322-331. doi:10.1016/j.jpainsymman.2006.05.012
70. Hu E, Kim JB, Sarraf P & Spiegelman BM 1996 Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARg. Science 274 2100-2103. doi:10.1126/science.274.5295.2100
71. Jatoi A, Loprinzi CL, Sloan JA, Klee GG & Windschitl HE 2001 Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation. Cancer 92 629-633. doi:10.1002/ 1097-01422001080192:3!629::AID-CNCR1363O3.0.CO;2-M
72. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, Mattar BI & Loprinzi CL 2010 A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients N01C9. Lung Cancer 68 234-239. doi:10.1016/j.lungcan.2009.06.020
73. Johns N, Stephens NA & Fearon KC 2013 Muscle wasting in cancer. International Journal of Biochemistry & Cell Biology 45 2215-2229. doi:10.1016/j.biocel.2013.05.032
74. Joppa MA, Ling N, Chen C, Gogas KR, Foster AC & Markison S 2005 Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia. Peptides 26 2294-2301. doi:10.1016/j.peptides.2005.03.002
75. Joppa MA, Gogas KR, Foster AC & Markison S 2007 Central infusion of the melanocortin receptor antagonist agouti-related peptide AgRP83- 132 prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice. Peptides 28 636-642. doi:10.1016/j.peptides. 2006.11.021
76. Kahn BB, Alquier T, Carling D & Hardie DG 2005 AMP-activated protein kinase: ancient energy gauge provides clues tomodern understanding of metabolism. Cell Metabolism 1 15-25. doi:10.1016/j.cmet.2004.12.003
77. Keifer JA, Guttridge DC, Ashburner BP & Baldwin AS 2001 Inhibition of NFkB activity by thalidomide through suppression of IkB kinase activity. Journal of Biological Chemistry 276 22382-22387. doi:10.1074/jbc. M100938200
78. Kir S, White JP, Kleiner S, Kazak L, Cohen P, Baracos VE & Spiegelman BM 2014 Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513 100-104. doi:10.1038/ nature13528
79. Kluger MJ 1991 Fever: role of pyrogens and cryogens. Physiological Reviews 71 93-127.
80. Kumar A, Bhatnagar S & Paul PK 2012 TWEAK and TRAF6 regulate skeletal muscle atrophy. Current Opinion in Clinical Nutrition and Metabolic Care 15 233-239. doi:10.1097/MCO.0b013e328351c3fc
81. Lage R, Diéguez C, Vidal-Puig A & López M 2008 AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends in MolecularMedicine 14 539-549. doi:10.1016/j.molmed.2008.09.007
82. Laviano A, Renvyle T, Meguid MM, Yang ZJ, Cangiano C & Rossi Fanelli F 1995 Relationship between interleukin-1 and cancer anorexia. Nutrition 11 680-683.
83. Laviano A, Cangiano C, Preziosa I, Meguid MM, Muscaritoli M, Conversano L, Cascino A, Torelli GF, Cherubini S & Rossi Fanelli F 1996 Serotoninergic block in the ventromedial nucleus of hypothalamus improves food intake in anorectic tumor bearing rats. Advances in Experimental Medicine and Biology 398 551-553. doi:10.1007/978-1- 4613-0381-7_88
84. Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C & Rossi Fanelli F 2000 Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. Journal of Investigative Medicine 48 40-48.
85. Laviano A, Meguid MM, Gleason JR & Rossi-Fanelli F 2002 VMN/LHA functional inhibition in tumor-bearing rats suggests hypothalamic involvement in cancer anorexia. Nutritional Neuroscience 5 443-456. doi:10.1080/1028415021000039202
86. Laviano A, Meguid MM & Rossi-Fanelli F 2003 Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet. Oncology 4 686-694. doi:10.1016/S1470-20450301247-6
87. Laviano A, Inui A, Marks DL, Meguid MM, Pichard C, Rossi Fanelli F & Seelaender M 2008 Neural control of the anorexia-cachexia syndrome. American Journal of Physiology. Endocrinology and Metabolism 295 E1000-E1008. doi:10.1152/ajpendo.90252.2008
88. Laviano A, Seelaender M, Rianda S, Silverio R & Rossi Fanelli F 2012 Neuroinflammation: a contributing factor to the pathogenesis of cancer cachexia. Critical Reviews in Oncogenesis 17 247-251. doi:10.1615/CritRevOncog.v17.i3.20
89. Lawrence CB & Rothwell NJ 2001 Anorexic but not pyrogenic actions of interleukin-1 are modulated by central melanocortin-3/4 receptors in the rat. Journal of Neuroendocrinology 13 490-495. doi:10.1046/j.1365- 2826.2001.00660.x
90. Li YP, Chen Y, Li AS & Reid MB 2003 Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. American Journal of Physiology. Cell Physiology 285 C806-C812. doi:10.1152/ajpcell.00129.2003
91. López M, Varela L, Vázquez MJ, Rodríguez-Cuenca S, González CR, Velagapudi VR, Morgan DA, Schoenmakers E, Agassandian K, Lage R et al. 2010 Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nature Medicine 16 1001-1008. doi:10.1038/nm.2207
92. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM, Camoriano JK, Novotny PJ & Christensen BJ 1999 Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology 17 3299-3306.
93. Loumaye A, de Barsy M, Nachit M, Lause P, Frateur L, van Maanen A, Trefois P, Gruson D & Thissen JP 2015 Role of activin A and myostatin in human cancer cachexia. Journal of Clinical Endocrinology and Metabolism 100 2030-2038. doi:10.1210/jc.2014-4318
94. Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J & Salehian B 2003 Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. American Journal of Physiology. Endocrinology and Metabolism 285 E363-E371. doi:10.1152/ajpendo.00487.2002
95. Machado AP, Costa Rosa LF & Seelaender MC 2004 Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell and Tissue Research 318 503-514. doi:10.1007/s00441-004-0987-2
96. Makarenko IG, Meguid MM, Gatto L, Goncalves CG, Ramos EJ, Chen C & Ugrumov MV 2005 Hypothalamic 5-HT1B-receptor changes in anorectic tumor bearing rats. Neuroscience Letters 376 71-75. doi:10.1016/j.neulet.2004.11.026
97. Mantovani G, Macció A, Massa E & Madeddu C 2001 Managing cancerrelated anorexia/cachexia. Drugs 61 499-514. doi:10.2165/00003495- 200161040-00004
98. Mantovani G, Macció A, Madeddu C, Gramignano G, Serpe R, Massa E, DessíM, Tanca FM, Sanna E, Deiana L et al. 2008 Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 24 305-313. doi:10.1016/j.nut. 2007.12.010
99. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SR, Fleck BA, Brown BT & Marks DL 2005 The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 146 2766-2773. doi:10.1210/en.2005-0142
100. Marks DL, Ling N & Cone RD 2001 Role of the central melanocortin system in cachexia. Cancer Research 61 1432-1438.
101. Marks DL, Butler AA, Turner R, Brookhart G & Cone RD 2003 Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 144 1513-1523. doi:10.1210/en.2002-221099
102. Martínez D, Pentinat T, Ribó S, Daviaud C, Bloks VW, Cebria` J, Villalmanzo N, Kalko SG, Ramón-Krauel M, Díaz R et al. 2014 In utero undernutrition in male mice programs liver lipid metabolism in the second-generation offspring involving altered Lxra DNA methylation. Cell Metabolism 19 941-951. doi:10.1016/j.cmet.2014.03.026
103. Masuno H, Yamasaki N & Okuda H 1981 Purification and characterization of a lipolytic factor toxohormone-L from cell-free fluid of ascites sarcoma 180. Cancer Research 41 284-288.
104. Masuno H, Yoshimura H, Ogawa N & Okuda H 1984 Isolation of a lipolytic factor toxohormone-L from ascites fluid of patients with hepatoma and its effect on feeding behavior. European Journal of Cancer & Clinical Oncology 20 1177-1185. doi:10.1016/0277-53798490127-5
105. Matthys P, Heremans H, Opdenakker G & Billiau A 1991 Anti-interferon-g antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. European Journal of Cancer 27 182-187. doi:10.1016/0277-53799190483-T
106. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H & Bradley A 1994 Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. PNAS 91 8817-8821. doi:10.1073/pnas.91.19. 8817
107. McCarthy HD, Crowder RE, Dryden S & Williams G 1994 Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. European Journal of Pharmacology 265 99-102. doi:10.1016/0014-29999490229-1
108. McDevitt TM, Todorov PT, Beck SA, Khan SH & Tisdale MJ 1995 Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Research 55 1458-1463.
109. McPherron AC & Lee SJ 1997 Double muscling in cattle due to mutations in the myostatin gene. PNAS 94 12457-12461. doi:10.1073/pnas.94.23. 12457
110. McPherron AC, Lawler AM & Lee SJ 1997 Regulation of skeletal muscle mass in mice by a new TGF-b superfamily member. Nature 387 83-90. doi:10.1038/387083a0
111. Menyhért J, Wittmann G, Lechan RM, Keller E, Liposits Z & Fekete C 2007 Cocaine- and amphetamine-regulated transcript CART is colocalized with the orexigenic neuropeptide Y and agouti-related protein and absent from the anorexigenic a-melanocyte-stimulating hormone neurons in the infundibular nucleus of the human hypothalamus. Endocrinology 148 4276-4281. doi:10.1210/en.2007-0390
112. Miller NE 1957 Experiments on motivation. Studies combining psychological, physiological, and pharmacological techniques. Science 126 1271-1278. doi:10.1126/science.126.3286.1271
113. Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H, Makonchuk DY & Glass DJ 2010 The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. Journal of Cell Biology 188 833-849. doi:10.1083/jcb.200909117
114. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA & Kaplan G 1993 Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. Journal of Experimental Medicine 177 1675-1680. doi:10.1084/jem.177.6.1675
115. Mourkioti F, Kratsios P, Luedde T, Song YH, Delafontaine P, Adami R, Parente V, Bottinelli R, Pasparakis M & Rosenthal N 2006 Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. Journal of Clinical Investigation 116 2945-2954. doi:10.1172/JCI28721
116. Murray MJ & Murray AB 1979 Anorexia of infection as a mechanism of host defense. American Journal of Clinical Nutrition 32 593-596.
117. Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P et al. 2010 Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups SIG "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clinical Nutrition 29 154-159. doi:10.1016/j.clnu.2009.12.004
118. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC & Bloom SR 2004 Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 89 2832-2836. doi:10.1210/jc.2003-031768
119. Nedergaard J & Cannon B 2014 The browning of white adipose tissue: some burning issues. Cell Metabolism 20 396-407. doi:10.1016/j.cmet.2014. 07.005
120. Nitenberg G & Raynard B 2000 Nutritional support of the cancer patient: issues and dilemmas. Critical Reviews in Oncology/Hematology 34 137-168. doi:10.1016/S1040-84280000048-2
121. Nobes JP, Langley SE, Klopper T, Russell-Jones D & Laing RW 2012 A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU International 109 1495-1502. doi:10.1111/j.1464-410X.2011.10555.x
122. Oliff A, Defeo-Jones D, BoyerM,Martinez D, Kiefer D, Vuocolo G,Wolfe A & Socher SH 1987 Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50 555-563. doi:10.1016/0092-86748790028-6
123. Opara EI, Laviano A & Meguid MM 1995a Correlation between food intake and cerebrospinal fluid interleukin 1a in anorectic tumor-bearing rats. Nutrition 11 678-679.
124. Opara EI, Laviano A, Meguid MM & Yang ZJ 1995b Correlation between food intake and CSF IL-1a in anorectic tumor bearing rats. Neuroreport 6 750-752. doi:10.1097/00001756-199503270-00011
125. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, Kliewer SA & Mangelsdorf DJ 2014 FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metabolism 20 670-677. doi:10.1016/j.cmet.2014.07.012
126. Parle M, Maguire P & Heaven C 1997 The development of a training model to improve health professionals' skills, self-efficacy and outcome expectancies when communicating with cancer patients. Social Science & Medicine 44 231-240. doi:10.1016/S0277-95369600148-7
127. Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G et al. 2014 A switch from white to brown fat increases energy expenditure in cancerassociated cachexia. Cell Metabolism 20 433-447. doi:10.1016/j.cmet. 2014.06.011
128. Pimentel GD, Ropelle ER, Rocha GZ & Carvalheira JB 2013 The role of neuronal AMPK as a mediator of nutritional regulation of food intake and energy homeostasis. Metabolism 62 171-178. doi:10.1016/j. metabol.2012.07.001
129. Pimentel GD, Ganeshan K & Carvalheira JB 2014 Hypothalamic inflammation and the central nervous system control of energy homeostasis. Molecular and Cellular Endocrinology 397 15-22. doi:10.1016/j.mce. 2014.06.005
130. Popiela T, Lucchi R & Giongo F 1989 Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. European Journal of Cancer & Clinical Oncology 25 1823-1829. doi:10.1016/0277-53798990354-4
131. Porporato PE, Filigheddu N, Reano S, Ferrara M, Angelino E, Gnocchi VF, Prodam F, Ronchi G, Fagoonee S, Fornaro M et al. 2013 Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice. Journal of Clinical Investigation 123 611-622. doi:10.1172/JCI39920
132. Price SR, Olivecrona T & Pekala PH 1986 Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor - the primary regulatory role of the hormone in 3T3-L1 adipocytes. Archives of Biochemistry and Biophysics 251 738-746. doi:10.1016/0003- 98618690384-X
133. Protas PT, Holownia A, Muszynska-Roslan K,Wielgat P, Krawczuk-RybakM & Braszko JJ 2011 Cerebrospinal fluid IL-6, TNF-a and MCP-1 in children with acute lymphoblastic leukaemia during chemotherapy. Neuropediatrics 42 254-256. doi:10.1055/s-0031-1295477
134. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A & MeguidMM2004 Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Current Opinion in Clinical Nutrition and Metabolic Care 7 427-434. doi:10.1097/ 01.mco.0000134363.53782.cb
135. Ranson SW, Fisher C & Ingram WR 1938 Adiposity and diabetes mellitus in a monkey with hypothalamic lesions. Endocrinology 23 7. doi:10.1210/ endo-23-2-175
136. Reid J, McKenna H, Fitzsimons D & McCance T 2009 Fighting over food: patient and family understanding of cancer cachexia. Oncology Nursing Forum 36 439-445. doi:10.1188/09.ONF.439-445
137. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ & Donnelly M 2012 Thalidomide for managing cancer cachexia. In Cochrane Database of Systematic Reviews CD008664. doi:10.1002/14651858. CD008664.pub2
138. Reyes TM & Sawchenko PE 2002 Involvement of the arcuate nucleus of the hypothalamus in interleukin-1-induced anorexia. Journal of Neuroscience 22 5091-5099.
139. Richardson P, Hideshima T & Anderson K 2002 Thalidomide: emerging role in cancer medicine. Annual Review of Medicine 53 629-657. doi:10.1146/annurev.med.53.082901.104043
140. Ropelle ER, Pauli JR, Zecchin KG, Ueno M, de Souza CT, Morari J, FariaMC, Velloso LA, Saad MJ & Carvalheira JB 2007 A central role for neuronal adenosine 50-monophosphate-activated proteinkinase incancer-induced anorexia. Endocrinology 148 5220-5229. doi:10.1210/en.2007-0381
141. Ropelle ER, FernandesMF, Flores MB, Ueno M, Rocco S, Marin R, Cintra DE, Velloso LA, Franchini KG, Saad MJ et al. 2008a Central exercise action increases the AMPK and mTOR response to leptin. PLoS ONE 3 e3856. doi:10.1371/journal.pone.0003856
142. Ropelle ER, Pauli JR, Fernandes MF, Rocco SA, Marin RM, Morari J, Souza KK, Dias MM, Gomes-Marcondes MC, Gontijo JA et al. 2008b A central role for neuronal AMP-activated protein kinase AMPK and mammalian target of rapamycin mTOR in high-protein diet-induced weight loss. Diabetes 57 594-605. doi:10.2337/db07-0573
143. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE & O'Brien ME 2004 Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? British Journal of Cancer 90 1905-1911. doi:10.1038/sj.bjc.6601781
144. Ruan HB, Dietrich MO, Liu ZW, Zimmer MR, Li MD, Singh JP, Zhang K, Yin R, Wu J, Horvath TL et al. 2014 O-GlcNA transferase enables AgRP neurons to suppress browning of white fat. Cell 159 306-317. doi:10.1016/j.cell.2014.09.010
145. Ruiz GV, Ló pez-Briz E, Carbonell SR, Gonzalvez PJL & Bort-Marti S 2013 Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews CD004310. doi:10.1002/ 14651858.CD004310.pub3
146. Russell ST & Tisdale MJ 2002 Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. British Journal of Cancer 87 580-584. doi:10.1038/sj.bjc.6600493
147. Russell ST & Tisdale MJ 2010 Antidiabetic properties of zinc-a2-glycoprotein in ob/ob mice. Endocrinology 151 948-957. doi:10.1210/en. 2009-0827
148. Russell ST, Hirai K & Tisdale MJ 2002 Role of b3-adrenergic receptors in the action of a tumour lipid mobilizing factor. British Journal of Cancer 86 424-428. doi:10.1038/sj.bjc.6600086
149. Russell ST, Zimmerman TP, Domin BA & Tisdale MJ 2004 Induction of lipolysis in vitro and loss of body fat in vivo by zinc-a2-glycoprotein. Biochimica et Biophysica Acta 1636 59-68. doi:10.1016/j.bbalip.2003. 12.004
150. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH & Goldberg AL 2004 Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 399-412. doi:10.1016/S0092- 86740400400-3
151. SandriM, Lin J, Handschin C, YangW, Arany ZP, Lecker SH, Goldberg AL & Spiegelman BM 2006 PGC-1a protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. PNAS 103 16260-16265. doi:10.1073/pnas.0607795103
152. Santos GA, Moura RF, Vitorino DC, Roman EA, Torsoni AS, Velloso LA & Torsoni MA 2013 Hypothalamic AMPK activation blocks lipopolysaccharide inhibition of glucose production in mice liver. Molecular and Cellular Endocrinology 381 88-96. doi:10.1016/j.mce. 2013.07.018
153. Saper CB & Breder CD 1992 Endogenous pyrogens in the CNS: role in the febrile response. Progress in Brain Research 93 419-428 discussion 428-429. doi:10.1016/S0079-61230864587-2
154. Saper CB & Breder CD 1994 The neurologic basis of fever. New England Journal of Medicine 330 1880-1886. doi:10.1056/ NEJM199406303302609
155. Sato T, Meguid MM, Fetissov SO, Chen C & Zhang L 2001 Hypothalamic dopaminergic receptor expressions in anorexia of tumor-bearing rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 281 R1907-R1916.
156. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF, Cowley MA & Marks DL 2007 Regulation of central melanocortin signaling by interleukin-1b. Endocrinology 148 4217-4225. doi:10.1210/en. 2007-0017
157. Schreck R, Rieber P & Baeuerle PA 1991 Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO Journal 10 2247-2258.
158. Schwartz MW, Woods SC, Porte D, Seeley RJ & Baskin DG 2000 Central nervous system control of food intake. Nature 404 661-671. doi:10.1038/35007534
159. Seruga B, Zhang H, Bernstein LJ & Tannock IF 2008 Cytokines and their relationship to the symptoms and outcome of cancer. Nature Reviews. Cancer 8 887-899. doi:10.1038/nrc2507
160. Shih A & Jackson KC 2007 Role of corticosteroids in palliative care. Journal of Pain & Palliative Care Pharmacotherapy 21 69-76. doi:10.1080/J354v21n04_14
161. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, KojimaM, Kangawa K & Kohno N 2003 Increased plasma ghrelin level in lung cancer cachexia. Clinical Cancer Research 9 774-778.
162. Silva VR, Micheletti TO, Pimentel GD, Katashima CK, Lenhare L, Morari J, Mendes MC, Razolli DS, Rocha GZ, de Souza CT et al. 2014 Hypothalamic S1P/S1PR1 axis controls energy homeostasis. Nature Communications 5 4859. doi:10.1038/ncomms5859
163. Sishi BJ & Engelbrecht AM 2011 Tumor necrosis factor alpha TNF-a inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine 54 173-184. doi:10.1016/j.cyto. 2011.01.009
164. Smith HJ, Wyke SM & Tisdale MJ 2004 Role of protein kinase C and NF-kB in proteolysis-inducing factor-induced proteasome expression in C2C12 myotubes. British Journal of Cancer 90 1850-1857. doi:10.1038/sj.bjc. 6601767
165. Soda K, Kawakami M, Kashii A & Miyata M 1994 Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin- 6 as the sole inducer of cachexia. Japanese Journal of Cancer Research 85 1124-1130. doi:10.1111/j.1349-7006.1994.tb02917.x
166. Soda K, Kawakami M, Kashii A & Miyata M 1995 Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. International Journal of Cancer 62 332-336. doi:10.1002/ijc.2910620317
167. Souza SC, de Vargas LM, Yamamoto MT, Lien P, Franciosa MD, Moss LG & Greenberg AS 1998 Overexpression of perilipin A and B blocks the ability of tumor necrosis factor a to increase lipolysis in 3T3-L1 adipocytes. Journal of Biological Chemistry 273 24665-24669. doi:10.1074/jbc.273.38.24665
168. Steinberg GR, Watt MJ & Febbraio MA 2009 Cytokine regulation of AMPK signalling. Frontiers in Bioscience 14 1902-1916. doi:10.2741/3350 Stewart GD, Skipworth RJ & Fearon KC 2006 Cancer cachexia and fatigue. Clinical Medicine 6 140-143. doi:10.7861/clinmedicine.6-2-140
169. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T et al. 2006 Comparison of orally administered Cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology 24 3394-3400. doi:10.1200/JCO.2005.05.1847
170. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschöp M, Kaufmann K, Holst B, Brändle M, von Moos R et al. 2008 Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancerrelated anorexia/cachexia: a randomised, placebo-controlled, doubleblind, double-crossover study. British Journal of Cancer 98 300-308. doi:10.1038/sj.bjc.6604148
171. Strassmann G, Fong M, Kenney JS & Jacob CO 1992 Evidence for the involvement of interleukin 6 in experimental cancer cachexia. Journal of Clinical Investigation 89 1681-1684. doi:10.1172/JCI115767
172. Suh SY, Choi YS, Yeom CH, Kwak SM, Yoon HM, Kim DG, Koh SJ, Park J, Lee MA, Lee YJ et al. 2013 Interleukin-6 but not tumour necrosis factoralpha predicts survival in patients with advanced cancer. Supportive Care in Cancer 21 3071-3077. doi:10.1007/s00520-013-1878-4
173. Taylor DD, Gercel-Taylor C, Jenis LG & Devereux DF 1992 Identification of a human tumor-derived lipolysis-promoting factor. Cancer Research 52 829-834.
174. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H & Aisner J 1992 Megestrol acetate in cancer anorexia and weight loss. Cancer 69 1268-1274. doi:10.1002/cncr.2820690532
175. Teng MN, Turksen K, Jacobs CA, Fuchs E & Schreiber H 1993 Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clinical Immunology and Immunopathology 69 215-222. doi:10.1006/ clin.1993.1172
176. Teunissen SC,Wesker W, Kruitwagen C, de Haes HC, Voest EE & de Graeff A 2007 Symptom prevalence in patients with incurable cancer: a systematic review. Journal of Pain and Symptom Management 34 94-104. doi:10.1016/j.jpainsymman.2006.10.015
177. Tisdale MJ 2003 The 'cancer cachectic factor'. Supportive Care in Cancer 11 73-78. doi:10.1007/s00520-002-0408-6
178. Tisdale MJ 2004 Cancer cachexia. Langenbeck's Archives of Surgery 389 299-305. doi:10.1007/s00423-004-0486-7
179. Tisdale MJ 2009 Mechanisms of cancer cachexia. Physiological Reviews 89 381-410. doi:10.1152/physrev.00016.2008
180. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K & Tisdale M 1996 Characterization of a cancer cachectic factor. Nature 379 739-742. doi:10.1038/379739a0
181. Torelli GF, Meguid MM, Moldawer LL, Edwards CK, Kim HJ, Carter JL, Laviano A & Rossi Fanelli F 1999 Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. American Journal of Physiology 277 R850-R855.
182. Tsoli M, Moore M, Burg D, Painter A, Taylor R, Lockie SH, Turner N, Warren A, Cooney G, Oldfield B et al. 2012 Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Research 72 4372-4382. doi:10.1158/0008-5472.CAN-11-3536
183. Varma M, Laviano A, Meguid MM, Gleason JR, Yang ZJ & Oler A 2000 Comparison of early feeding pattern dynamics in female and male rats after reversible ventromedial nucleus of hypothalamus block. Journal of Investigative Medicine 48 417-426.
184. Wang DT, Yin Y, Yang YJ, Lv PJ, Shi Y, Lu L & Wei LB 2014 Resveratrol prevents TNF-a-induced muscle atrophy via regulation of Akt/mTOR/ FoxO1 signaling in C2C12 myotubes. International Immunopharmacology 19 206-213. doi:10.1016/j.intimp.2014.02.002
185. Watanabe S & Bruera E 1996 Anorexia and cachexia, asthenia, and lethargy. Hematology/Oncology Clinics of North America 10 189-206. doi:10.1016/S0889-85880570334-8
186. Weiland TJ, Anthony-Harvey-Beavis D, Voudouris NJ & Kent S 2006 Metabotropic glutamate receptors mediate lipopolysaccharide-induced fever and sickness behavior. Brain, Behavior, and Immunity 20 233-245. doi:10.1016/j.bbi.2005.08.007
187. Whitaker KW& Reyes TM 2008 Central blockade ofmelanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1b administration. Neuropharmacology 54 509-520. doi:10.1016/j.neuropharm.2007.10.014
188. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M et al. 2008 A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. Journal of Supportive Oncology 6 18-25.
189. Wieland BM, Stewart GD, Skipworth RJ, Sangster K, Fearon KC, Ross JA, Reiman TJ, Easaw J, Mourtzakis M, Kumar V et al. 2007 Is there a human homologue to the murine proteolysis-inducing factor? Clinical Cancer Research 13 4984-4992. doi:10.1158/1078-0432.CCR- 07-0946
190. Winter A, MacAdams J & Chevalier S 2012 Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clinical Nutrition 31 765-773. doi:10.1016/ j.clnu.2012.05.003
191. Wisse BE, Frayo RS, Schwartz MW & Cummings DE 2001 Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142 3292-3301. doi:10.1210/endo.142.8.8324 Xia Y & Schneyer AL 2009 The biology of activin: recent advances in structure, regulation and function. Journal of Endocrinology 202 1-12. doi:10.1677/JOE-08-0549
192. YoshikawaT,Noguchi Y,DoiC,MakinoT&NomuraK 2001 Insulinresistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response,andenergyexpenditure.Nutrition 17 590-593. doi:10.1016/S0899-90070100561-5
193. Yu Z, Li P, Zhang M, Hannink M, Stamler JS & Yan Z 2008 Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli. PLoS ONE 3 e2086. doi:10.1371/journal.pone.0002086
194. Zaki MH, Nemeth JA & Trikha M 2004 CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. International Journal of Cancer 111 592-595. doi:10.1002/ijc.20270
195. Zhang HH, Halbleib M, Ahmad F, Manganiello VC & Greenberg AS 2002 Tumor necrosis factor-a stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51 2929-2935. doi:10.2337/ diabetes.51.10.2929
196. Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, Yao S, Ma Q, Jin L, Yang J et al. 2014 Berberine activates thermogenesis in white and brown adipose tissue. Nature Communications 5 5493. doi:10.1038/ ncomms6493
197. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, SimonetWS et al. 2010 Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142 531-543. doi:10.1016/j.cell.2010.07.011